Expression of X-linked inhibitor of apoptosis protein in neoplastic thyroid disorder

Journal of Korean Medical Science

Volumn 26, Issue 9, 2011, Pages 1191-1195

  Yim, Ji Hye ^a   Yoon, Jong Ho ^a   Kim, Sun A ^a   Kim, Won Gu ^a   Jeon, Min Ji ^a   Han, Ji Min ^a   Sung, Tae Yon ^a   Kim, Tae Yong ^a   Kim, Won Bae ^a   Hong, Suck Joon ^a   Shong, Young Kee ^a   Gong, Gyungyub ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Lymph nodes; Metastasis; Papillary thyroid carcinoma; Thyroid neoplasms; X linked Inhibitor of Apoptosis Protein

Indexed keywords

MONOCLONAL ANTIBODY; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; ARTICLE; CANCER STAGING; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; THYROID TUMOR;

ADULT; ANTIBODIES, MONOCLONAL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; THYROID NEOPLASMS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 80052812149     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2011.26.9.1191     Document Type: Article

References (30)

1. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007; 12: 1543-68.
2. Holcik M, Korneluk RG. XIAP, the guardian angel. Nat Rev Mol Cell Biol 2001; 2: 550-6.
3. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis 2001; 6: 253-61.
4. Bree RT, Stenson-Cox C, Grealy M, Byrnes L, Gorman AM, Samali A. Cellular longevity: role of apoptosis and replicative senescence. Biogerontology 2002; 3: 195-206.
5. Fulda S, Debatin KM. Apoptosis signaling in tumor therapy. Ann N Y Acad Sci 2004; 1028: 150-6.
6. Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 2005; 258: 479-517.
7. Kasibhatla S, Tseng B. Why target apoptosis in cancer treatment? Mol Cancer Ther 2003; 2: 573-80.
8. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-95.
9. Xiao GQ, Unger PD, Burstein DE. Immunohistochemical detection of X-linked inhibitor of apoptosis (XIAP) in neoplastic and other thyroid disorders. Ann Diagn Pathol 2007; 11: 235-40.
10. Gu LQ, Li FY, Zhao L, Liu Y, Chu Q, Zang XX, Liu JM, Ning G, Zhao YJ. Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma. Endocrine 2010; 38: 276-82.
11. CoreTeam D. A language and environment for statistical computing. Available at http://www.R-project.org [accessed on Dec 5 2007].
12. Baloch ZW, Sack MJ, Yu GH, Livolsi VA, Gupta PK. Fine-needle aspiration of thyroid: an institutional experience. Thyroid 1998; 8: 565-9.
13. Elliott DD, Pitman MB, Bloom L, Faquin WC. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: a cytomorphologic study of 139 cases with statistical analysis. Cancer 2006; 108: 102-9.
14. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
15. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006; 65: 364-8.
16. Kim SW, Lee JI, Kim JW, Ki CS, Oh YL, Choi YL, Shin JH, Kim HK, Jang HW, Chung JH. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab 2010; 95: 3693-700.
17. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 2006; 91: 3667-70.
18. Wiseman SM, Melck A, Masoudi H, Ghaidi F, Goldstein L, Gown A, Jones SJ, Griffith OL. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol 2008; 15: 2811-26.
19. Rossi ED, Raffaelli M, Mule' A, Miraglia A, Lombardi CP, Vecchio FM, Fadda G. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology 2006; 48: 795-800.
20. Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 2006; 126: 700-8.
21. Nga ME, Lim GS, Soh CH, Kumarasinghe MP. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol 2008; 36: 550-6.
22. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006; 6: 292-306.
23. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006; 30: 216-22.
24. Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 2010; 23: 1191-200.
25. Gu LQ, Li FY, Zhao L, Liu Y, Zang XX, Wang TX, Chen HP, Ning G, Zhao YJ. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma. Thyroid 2009; 19: 347-54.
26. Xiang G, Wen X, Wang H, Chen K, Liu H. Expression of X-linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis. J Surg Oncol 2009; 100: 708-12.
27. Ferreira CG, van der Valk P, Span SW, Ludwig I, Smit EF, Kruyt FA, Pinedo HM, van Tinteren H, Giaccone G. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res 2001; 7: 2468-74.
28. Ito Y, Miyauchi A. Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. Endocr J 2009; 56: 177-92.
29. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
30. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.